Intestinal Leiomyosarcoma Clinical Presentation
- Author: Jaspreet K Ghumman, DO; Chief Editor: BS Anand, MD more...
Symptoms are usually lacking; if present, they are nonspecific. Vague complaints, such as malaise, fatigue, and nonfocal abdominal pain, are often described.
The sign most often cited is bleeding. These tumors sometimes necrose and bleed into the bowel. In one study, 59% of patients with leiomyosarcomas were symptomatic. For 70% of these patients, bleeding was the primary symptom. Of those who bled, 69% bled acutely, and 82% of the acute bleeders required transfusions. Of those who bled acutely, 45% required emergent laparotomy. Duodenal tumors bled most often. Of the duodenal tumors, 75% bled, requiring an average replacement of 11.5 units of blood.
Complaints of malaise and fatigue likely are due to anemia, which often is present in patients who bleed chronically.
Weight loss is reported as a late feature, with an incidence of around 20%.
Past medical history: One study reported a possible relationship between leiomyosarcomas and Crohn disease. In this series, which reviewed more than 11,000 cases, 6% of the patients with leiomyosarcomas also had a history of Crohn disease.
Unless the patient is bleeding or is acutely obstructed, physical findings usually are absent.
A mass rarely is palpable.
Patients with malignancy may present with the findings of obstruction, such as distention, borborygmi, a palpable mass, and diffuse mild-to-moderate abdominal tenderness.
Other patients present with jaundice secondary to either biliary obstruction or hepatic replacement by metastases.
Cachexia, hepatomegaly, and ascites may be present in patients with advanced metastatic disease.
Aggarwal G, Sharma S, Zheng M, et al. Primary leiomyosarcomas of the gastrointestinal tract in the post-gastrointestinal stromal tumor era. Ann Diagn Pathol. 2012 Dec. 16(6):532-40. [Medline].
Martin RG. Malignant tumors of the small intestine. Surg Clin North Am. 1986 Aug. 66(4):779-85. [Medline].
DiSario JA, Burt RW, Vargas H, McWhorter WP. Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol. 1994 May. 89(5):699-701. [Medline].
Zhan J, Xia ZS, Zhong YQ, et al. Clinical analysis of primary small intestinal disease: A report of 309 cases. World J Gastroenterol. 2004 Sep 1. 10(17):2585-7. [Medline].
Hill MA, Mera R, Levine EA. Leiomyosarcoma: a 45-year review at Charity Hospital, New Orleans. Am Surg. 1998 Jan. 64(1):53-60; discussion 60-1. [Medline].
Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer. 1985 Nov 1. 56(9):2242-50. [Medline].
Ludwig DJ, Traverso LW. Gut stromal tumors and their clinical behavior. Am J Surg. 1997 May. 173(5):390-4. [Medline].
Miki Y, Kurokawa Y, Hirao M, Fujitani K, Iwasa Y, Mano M, et al. Survival analysis of patients with duodenal gastrointestinal stromal tumors. J Clin Gastroenterol. 2010 Feb. 44(2):97-101. [Medline].
Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer. 2006 Jul 1. 107(1):22-7. [Medline].
Yoshida S, Yamashita K, Yokozawa M, et al. Diagnostic findings of ultrasound-guided fine-needle aspiration cytology for gastrointestinal stromal tumors: proposal of a combined cytology with newly defined features and histology diagnosis. Pathol Int. 2009 Oct. 59(10):712-9. [Medline].
Tien YW, Lee CY, Huang CC, Hu RH, Lee PH. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol. 2010 Jan. 17(1):109-14. [Medline].
D'Adamo D. Advances in the treatment of gastrointestinal stromal tumor. Adv Ther. 2009 Sep. 26(9):826-37. [Medline].
Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009 Nov 15. 15(22):6862-70. [Medline]. [Full Text].
US Food and Drug Administration. FDA approves new therapy for certain types of advanced soft tissue sarcoma [news release]. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm. October 23, 2015; Accessed: January 11, 2016.
Demetri GD, von Mehren M, Jones RL, et al. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). Presented at 2015 Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois; May 29, 2015. J Clin Oncol. 2015. 33 (suppl):abstr 10503. [Full Text].
Zhou PH, Yao LQ, Zhong YS, et al. Role of endoscopic miniprobe ultrasonography in diagnosis of submucosal tumor of large intestine. World J Gastroenterol. 2004 Aug 15. 10(16):2444-6. [Medline].
Artigau Nieto E, Luna Aufroy A, et al. Gastrointestinal stromal tumors: experience in 49 patients. Clin Transl Oncol. 2006 Aug. 8(8):594-8. [Medline].
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14. 368(9544):1329-38. [Medline].
Yang WL, Yu JR, Wu YJ, et al. Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis. J Surg Oncol. 2009 Dec 1. 100(7):606-10. [Medline].
Zhan WH, Wang PZ, Shao YF, et al. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial] [Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Sep. 9(5):383-7. [Medline].
Fragulidis GP, Vezakis A, Chondrogiannis K, Mellou A, Melemeni A, Polydorou A. Clinical presentation and management of gastro-intestinal and pancreatic secondary metastatic tumors. J BUON. 2015 Jul-Aug. 20 (4):1009-14. [Medline].